



Public Assessment Report

National Procedure

Tezspire 210 mg solution for injection in pre-filled syringe

tezepelumab

PLGB 17901/0365

AstraZeneca UK Limited

LAY SUMMARY

Tezspire 210 mg solution for injection in pre-filled syringe tezepelumab

This is a summary of the Public Assessment Report (PAR) for Tezspire 210 mg solution for injection in pre-filled syringe. It explains how this product was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product.

This product will be referred to as Tezspire in this lay summary for ease of reading.

For practical information about using Tezspire, patients should read the Patient Information Leaflet (PIL) or contact their doctor or pharmacist.

What is Tezspire and what is it/they used for?

This product has been authorised by MHRA for Great Britain (consisting of England, Scotland and Wales). In coming to its decision, MHRA has relied on a European Commission (EC) decision on 19 September 2022 (EMA/H/C/005588/0000), in accordance with the advice from the Committee for Medicinal Products for Human Use (CHMP). This is known as the EC Decision Reliance Procedure.

Tezspire is used with other asthma medicines to treat severe asthma in adults and adolescents (12 years of age and older) when the disease is not controlled with their current asthma medicines.

Tezspire may reduce the number of asthma attacks, improve a patient's breathing and reduce their asthma symptoms.

How does Tezspire work?

Tezspire contains the active substance tezepelumab, which is a monoclonal antibody. Antibodies are proteins that recognise and bind to a specific target substance in the body, which in the case of tezepelumab is a protein called *thymic stromal lymphopoietin* (TSLP). TSLP plays a key role in causing the inflammation in the airways that leads to the signs and symptoms of asthma. By blocking the action of TSLP, this medicine helps to reduce inflammation and asthma symptoms.

How is Tezspire used?

The pharmaceutical form of this medicine is a solution for injection in pre-filled syringe and the route of administration is injection under the skin (subcutaneous injection).

Adults and adolescents aged 12 years and over:

The recommended dose is 210 mg (1 injection) every 4 weeks. Tezspire is given as an injection under the skin (subcutaneously).

The patient's doctor or nurse will decide if patient's caregiver or the patient should inject this medicine. The caregiver and/or the patient will receive training on the right way to prepare and inject Tezspire.

Before injecting Tezspire, the 'Instructions for Use' for Tezspire should be read carefully. Because new information may be included in the 'Instructions for Use' these should be read each time before patient receives another injection.

More than one Tezspire pre-filled syringe should not be used at a time. Tezspire pre-filled syringe syringes should not be shared.

For further information on how Tezspire is used, refer to the PIL and Summary of Product Characteristics (SmPC) available on the Medicines and Healthcare product Regulatory Agency (MHRA) website.

This medicine can only be obtained with a prescription.

The patient should ask the administering healthcare practitioner if they have any questions concerning their medicine.

What benefits of Tezspire have been shown in studies?

Two main studies including over 1,500 adults and adolescents with inadequately controlled asthma showed that Tezspire was effective in reducing the number of severe asthma flare-ups. In the first study, patients given Tezspire had on average 0.93 asthma flare-ups per year after one year of treatment compared with 2.10 in patients given placebo (a dummy treatment). In the second study, patients taking Tezspire had an average of 0.20 flare-ups per year after one year, compared with 0.72 in patients who received placebo.

What are the possible side effects of Tezspire?

For the full list of all side effects reported with this medicine, see Section 4 of the PIL or the SmPC available on the MHRA website.

If a patient gets any side effects, they should talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in the product information or the PIL that comes with the medicine. Patients can also report suspected side effects themselves, or a report can be made on their behalf by someone else who cares for them, directly via the Yellow Card scheme at <https://yellowcard.mhra.gov.uk> or search for 'MHRA Yellow Card' online. By reporting side effects, patients can help provide more information on the safety of this medicine.

The most common side effects with Tezspire (which may affect up to 1 in 10 people) are....

- sore throat
- rash
- joint pain
- injection site reaction (such as redness, swelling, and pain)

Why was Tezspire approved?

MHRA decided that the benefits are greater than the risks and recommended that this medicine can be approved for use. Tezspire has been authorised with the condition to perform further studies. See section below "What measures are being taken to ensure the safe and effective use of Tezspire?"

What measures are being taken to ensure the safe and effective use of Tezspire?

As for all newly-authorised medicines, a Risk Management Plan (RMP) has been developed for Tezspire. The RMP details the important risks of Tezspire, how these risks can be minimised, any uncertainties about Tezspire (missing information), and how more information will be obtained about the important risks and uncertainties.

The following safety concerns have been recognised for Tezspire:

Important identified risks	None
Important potential risks	Serious Infections Serious cardiac events Malignancy
Missing information	Use in pregnant and breastfeeding women Long-term use (> 1 year)

Additional pharmacovigilance activities are in place to carry out further studies in specific populations and to monitor efficacy with long-term use.

The information included in the SmPC and the PIL is compiled based on the available quality, non-clinical and clinical data, and includes appropriate precautions to be followed by healthcare professionals and patients. Side effects of Tezspire are continuously monitored and reviewed including all reports of suspected side-effects from patients, their carers, and healthcare professionals.

A (RMP) and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

Other information about Tezspire

A marketing authorisation was granted in **Great Britain** on 23 September 2022.

The full PAR for Tezspire follows this summary.

This summary was last updated in April 2023.

TABLE OF CONTENTS

I.	INTRODUCTION	6
II.	PRODUCT INFORMATION	6
III.	QUALITY ASPECTS	7
IV.	NON-CLINICAL ASPECTS	7
V.	CLINICAL ASPECTS	7
VI.	RISK MANAGEMENT PLAN (RMP)	7
VII.	USER CONSULTATION	8
VIII.	OVERALL CONCLUSION, BENEFIT/RISK AND RECOMMENDATION	8

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) considered that the application for Tezspire 210 mg solution for injection in pre-filled syringe (PLGB 17901/0365) could be approved.

The product is approved for the following indication:

As an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Mechanism of action

Tezepelumab is a monoclonal antibody (IgG2 λ) directed against thymic stromal lymphopoietin (TSLP), preventing its interaction with the heterodimeric TSLP receptor. In asthma, both allergic and non-allergic triggers induce TSLP production. Blocking TSLP with tezepelumab reduces a broad spectrum of biomarkers and cytokines associated with airway inflammation (e.g. blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13); however, the mechanism of action of tezepelumab in asthma has not been definitively established.

This product has been authorised by MHRA for Great Britain (consisting of England, Scotland and Wales). In coming to its decision, MHRA has relied on a European Commission (EC) decision on 19 September 2022 (EMA/H/C/005588/0000), in accordance with the advice from the Committee for Medicinal Products for Human Use (CHMP).

For the scientific discussion of the quality, non-clinical and clinical assessment conducted by the European Medicines Agency (EMA), please refer to the European Public Assessment Report, available on the EMA website.

This application was approved under Regulation 50 of the Human Medicines Regulation 2012, as amended (previously Article 8.3 of Directive 2001/83/EC, as amended).

In line with the legal requirements for children's medicines, the application included a licensing authority decision on the agreement of a paediatric investigation plan (PIP) *MHRA-100146-PIP01-21*.

At the time of the submission of the application the PIP was *under assessment*.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product at all sites responsible for the manufacture, assembly and batch release of this product.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

A marketing authorisation was granted on 23 September 2022.

II. PRODUCT INFORMATION

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

The SmPC is in line with current guidelines and is satisfactory.

PATIENT INFORMATION LEAFLET

The PIL is in line with current guidelines and is satisfactory.

LABEL

The labelling is in line with current guidelines and is satisfactory.

III. QUALITY ASPECTS

MHRA considered that the quality data submitted for this application is satisfactory.

The grant of a marketing authorisation is recommended.

IV. NON-CLINICAL ASPECTS

MHRA considered that the non-clinical data submitted for this application is satisfactory.

The grant of a marketing authorisation is recommended.

V. CLINICAL ASPECTS

MHRA considered that the clinical data submitted for this application is satisfactory.

The grant of a marketing authorisation is recommended.

VI. RISK MANAGEMENT PLAN (RMP)

The applicant has submitted an RMP, in accordance with the requirements of Regulation 182 of The Human Medicines Regulation 2012, as amended. In addition to routine pharmacovigilance and risk minimisation measures, the following additional pharmacovigilance activities have been proposed:

Safety concern	Risk minimisation measures	Pharmacovigilance activities
Important identified risks		
None		
Important potential risks		
Serious infections	Routine risk minimisation measures: SmPC Section 4.4 and Package Leaflet Section 2	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing targeted follow-up questionnaires Additional pharmacovigilance activities: Study D5180C00024 - 28-week OCS-reduction study in severe asthma Study D5180C00021 - 52-week China/Asia regional efficacy and safety study in severe asthma
Serious cardiac events	Routine risk minimisation measures: SmPC Section 4.4 and Package Leaflet Section 2	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing targeted follow-up questionnaires Additional pharmacovigilance activities: Study D5180C00024 - 28-week OCS-reduction study in severe asthma Study D5180C00021 - 52-week China/Asia regional efficacy and safety study in severe asthma Serious cardiac events post-authorisation safety study

Safety concern	Risk minimisation measures	Pharmacovigilance activities
Malignancy	Routine risk minimisation measures: None	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing targeted follow-up questionnaires Additional pharmacovigilance activities: Study D5180C00024 - 28-week OCS-reduction study in severe asthma Study D5180C00021 - 52-week China/Asia regional efficacy and safety study in severe asthma
Missing information		
Use in pregnancy and breastfeeding	Routine risk minimisation measures: SmPC Section 4.6 and Package Leaflet Section 2	Additional pharmacovigilance activity: Study D5180R00010 - Database study of the use (and safety) of tezepelumab in women with severe asthma during pregnancy
Long-term use (> 1 year)	Routine risk minimisation measures: None	Additional pharmacovigilance activity: Study D5180C00018 (DESTINATION) - Phase 3 safety extension study to evaluate the safety and tolerability of tezepelumab in adults and adolescents with severe uncontrolled asthma.

SmPC, Summary of Product Characteristics.

This is acceptable.

VII. USER CONSULTATION

A full colour mock-up of the Patient Information Leaflet (PIL) has been provided with the application, in accordance with legal requirements.

The PIL has been evaluated via a user consultation study in accordance with legal requirements. The results show that the PIL meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal product for human use.



VIII. OVERALL CONCLUSION, BENEFIT/RISK AND RECOMMENDATION

The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. The benefit/risk balance is, therefore, considered to be positive.

The Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and labelling are satisfactory.

In accordance with legal requirements, the current approved UK version of the SmPC and PIL for this product is available on the MHRA website.

Representative copies of the labels at the time of UK licensing are provided below.



The diagram shows a rectangular label for a pre-filled syringe. It features registration marks (crosshairs) at the top, bottom, left, and right centers. The label is divided into two main sections by a dashed blue border. The top section contains the product name and AstraZeneca logo. The bottom section contains detailed instructions for use and a 'GLUE AREA' on the right side.

TEZSPIRE 210 mg
solution for injection in pre-filled syringe
tezepelumab

Instructions for Use
This 'Instructions for Use' contains information on how to inject Tezspire.

AstraZeneca

Before you use your Tezspire pre-filled syringe, your healthcare provider should show you or your caregiver how to use it the right way.

Read this 'Instructions for Use' before you start using your Tezspire pre-filled syringe and each time you get another injection. There may be new information. This information should not replace talking to your healthcare provider about your medical condition and your treatment.

If you or your caregiver have any questions, talk to your healthcare provider.

GLUE AREA

Important information you need to know before injecting Tezspire

Store Tezspire in a refrigerator between 2°C to 8°C in its outer carton until you are ready to use it. Tezspire may be kept at room temperature between 20°C to 25°C in the outer carton for a maximum of 30 days.

Once Tezspire has reached room temperature, **do not** put it back in the refrigerator. Throw away (dispose of) Tezspire that has been stored at room temperature for more than 30 days (see Step 10).

Do not use your Tezspire pre-filled syringe if:

- it has been frozen
- it has been dropped or damaged
- the security seal on the carton has been broken
- the expiry date (EXP) has passed

Do not shake your pre-filled syringe.

Do not share your pre-filled syringe or use it more than 1 time.

Do not expose your Tezspire pre-filled syringe to heat.

If any of the above happens, throw away the syringe in a puncture-resistant (sharps) container and use a new Tezspire pre-filled syringe.

Each Tezspire pre-filled syringe contains 1 dose of Tezspire that can only be used 1 time.

Keep Tezspire pre-filled syringe and all medicines out of the sight and reach of children.


Tezspire is given only as an injection under the skin (subcutaneous).

GLUE AREA

Your Tezspire pre-filled syringe

Do not remove the needle cover until Step 7 of these instructions when you are ready to inject Tezspire.

Do not touch the needle guard activation clips. This will keep you from activating the safety device (needle guard) too soon.




GLUE AREA


GLUE AREA

Preparing to inject Tezspire
 Step 1 – Gather supplies


- 1 Tezspire pre-filled syringe from the refrigerator
- 1 alcohol wipe
- 1 cotton ball or gauze
- 1 small bandage (optional)
- 1 puncture-resistant (sharps) disposal container. See Step 10 for instructions on how to throw away (dispose of) the used Tezspire pre-filled syringe safely.




Pre-filled syringe




Alcohol wipe



Cotton ball or gauze



Bandage



Sharps disposal container

1

2

3

4

5

6

7

8

9

10

GLUE AREA

Step 2 – Prepare to use your Tezspire pre-filled syringe


2 Let Tezspire come to room temperature between 20°C to 25°C for about 60 minutes or longer (up to a maximum of 30 days) before giving the injection.

Keep the pre-filled syringe in the outer carton in order to protect from light.

Do not warm the pre-filled syringe in any other way. For example, **do not** warm it in a microwave or hot water, in direct sunlight, or near other heat sources.

Do not put Tezspire back in the refrigerator after it has reached room temperature. Throw away (dispose of) Tezspire that has been stored at room temperature for more than 30 days.

Do not remove the needle cover until Step 7.



1

2

3

4

5

6

7


8

9

10

Step 3 – Remove pre-filled syringe

Grab the syringe body to remove the pre-filled syringe from its tray. **Do not** grab the pre-filled syringe by the plunger.



GLUE AREA

- 1
- 2
- 3**
- 4
- 5
- 6
- 7
- 8
- 9
- 10

Step 4 – Check the pre-filled syringe


Check the pre-filled syringe for damage. Do not use the pre-filled syringe if the pre-filled syringe is damaged.

Check the expiry date on the pre-filled syringe. Do not use the pre-filled syringe if the expiry date has passed.

Look at the liquid through the viewing window. The liquid should be clear and colourless to light yellow.

Do not inject Tezpire if the liquid is cloudy, discoloured, or contains large particles.

You may see small air bubbles in the liquid. This is normal. You do not need to do anything about it.



GLUE AREA

- 1**
- 2
- 3
- 4**
- 5
- 6
- 7
- 8
- 9
- 10

⊕

GLUE AREA

Step 7 – Pull off the needle cover

Do not remove the cap until you are ready to inject. Hold the syringe body with 1 hand, and carefully pull the needle cover straight off with your other hand.

Do not hold the plunger or plunger head while removing the needle cover.


Put the needle cover to the side and throw it away later.

You may see a drop of liquid at the end of the needle. This is normal.

Do not touch the needle or let it touch any surface.

Do not put the needle cover back on the syringe.

1
2
3
4
5
6
7
8
9
10



⊕

⊕

⊕

GLUE AREA

Step 8 – Inject Tezspire

Hold the pre-filled syringe in 1 hand as shown.


Use your other hand to gently pinch and hold the area of skin where you want to inject. This will make the skin firmer.

Do not press down on the plunger head until the needle is inserted into the skin.

Do not pull back on the plunger head at any time.

Inject Tezspire by following the steps in figures a, b and c.




1
2
3
4
5
6
7
8
9
10



GLUE AREA

⊕

⊕

GLUE AREA	a		b		c		1
						2	
						3	
						4	
						5	
						6	
						7	
						8	
						9	
						10	


Using a 45 degree angle, fully insert the needle into the pinched skin.
Do not try to change the position of the pre-filled syringe after you insert it into the skin.

Use your thumb to push down on the plunger head.
Keep pushing until it is down as far as it will go to make sure you inject all of the medicine.

Keep your thumb pressed down on the plunger head as you take the needle out of the skin.
Slowly let go of the plunger until the needle guard covers the needle.

⊕

⊕

1	Step 9 – Check the injection site	GLUE AREA
2	There may be a small amount of blood or liquid where you injected. This is normal.	
3	Gently hold pressure over your skin with a cotton ball or gauze until the bleeding stops.	
4	Do not rub the injection site. If needed, cover the injection site with a small bandage.	
5		
6		
7		
8		
9		
10		

⊕



TABLE OF CONTENT OF THE PAR UPDATE

Steps taken after the initial procedure with an influence on the Public Assessment Report (non-safety variations of clinical significance).

Please note that only non-safety variations of clinical significance are recorded below and in the annexes to this PAR. The assessment of safety variations, where significant changes are made, are recorded on the MHRA website or European Medicines Agency (EMA) website. Minor changes to the marketing authorisation are recorded in the current SmPCs and/or PIL available on the MHRA website.

Application type	Scope	Product information affected	Date of grant	Outcome	Assessment report attached Y/N

/